Vanta Bioscience is currently trading at Rs. 194.00, up by 9.00 points or 4.86% from its previous closing of Rs. 185.00 on the BSE.
The scrip opened at Rs. 186.00 and has touched a high and low of Rs. 194.00 and Rs. 183.00 respectively. So far 7500 shares were traded on the counter.
The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 194.00 on 08-Apr-2019 and a 52 week low of Rs. 46.00 on 07-Jun-2018.
Last one week high and low of the scrip stood at Rs. 194.00 and Rs. 142.00 respectively. The current market cap of the company is Rs. 122.45 crore.
The promoters holding in the company stood at 72.45%, while Non-Institutions held 27.55% stake in the company.
Vanta Bioscience through its step down subsidiary -- Vayam Research Solutions has entered into a non-exclusive CRO Service Agreement with Emcure Pharmaceuticals, Pune, for providing services of Bio-Analytical and Bio-Equivalence services to the said company for a period of three years from 2019 to 2022.
The CRO Service Agreement provides for a minimum revenue assurance between Rs 7 crore to Rs 9 crore for the financial year 2019-2020 and Rs 20 crore for financial year 2020-2021.
Vanta Bioscience is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries.
| Company Name | CMP |
|---|---|
| Syngene Internatl. | 440.25 |
| Indegene | 508.80 |
| CMS Info Systems | 274.35 |
| JITF Infralogistics | 304.90 |
| Sagility | 40.99 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: